Company and Strategy

Pro Bono Bio PLC (‘PBB’) is an international nano-lipid, healthcare technology and products company, therapeutically focused on haematology and pain relief

  • We are developing, innovative blood factor products and therapies for the treatment of Haemophilia A across the spectrum of patients, particularly those who have developed inhibitors to conventional treatments.
  • Our marketed medical device products address joint pain conditions, including osteoarthritis in a novel way to traditional pharmaceuticals, resulting in advantages to long-term efficacy and safety.
  • Our strategy is to leverage our unique expertise in these separate high value market segments:
    • in our clinical development programmes for the treatment of Haemophilia A by progressing our Phase 2 trials, in internationally recognised centres of excellence, through to completion yielding significant value inflection; and
    • in our range of ‘FLEXISEQ’ branded medical device products by expanding our distribution globally through partnering with international distributors in key markets under innovative commercial arrangements, with carefully targeted advertising and promotional spend, to rapidly build profitable market share; and
    • by protecting our intellectual property estate so that our nano-lipid technology can be extended into other areas for future exploitation, to deliver substantial shareholder value.